A digital therapeutic (DTx) that aims to treat negative symptoms of schizophrenia, like apathy and social withdrawal, has hit the target in a phase 3 trial. The smartphone-based CT-155 app, ...
French biotech Pharnext has seen the value of its shares collapse after it revealed that its lead drug, a treatment for Charcot-Marie-Tooth (CMT) disease, failed to make the grade in a phase 3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback